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other pathogens, could influence the susceptibility to the athero-
genic effect of infection with a particular pathogen like CP.
Consequently, this finding suggests that “susceptibility” factors
could make subjects more likely to develop CAD when infected
with a particular pathogenic agent.
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REPLY
We greatly appreciate the comments of Dr. Auer and colleagues
regarding our article recently published in the Journal of the
American College of Cardiology (1).
Chlamydia pneumoniae (CP) was often reported to be associated
with coronary artery disease (CAD) in seroepidemiologic studies,
but the potential contribution of CP to CAD remains controver-
sial. As shown in our article (1), Auer et al. also found no
significant difference in the CAD prevalence between patients with
and without CP seropositivity. However, CP organism was de-
tected within atheroma by direct immunofluorescence and poly-
merase chain reaction (PCR), and CP infection was shown to
accelerate atherosclerosis in a rabbit model. We agree with Dr.
Auer and colleagues that some triggers like cytokine gene poly-
morphisms or additional exposure to other pathogens could
influence susceptibility to the atherogenic effect of CP infection.
Regarding genetic factors for CAD associated with CP infec-
tion, we reported that two polymorphisms of interleukin (IL)-1
genes play a role in the development of CAD, especially myocar-
dial infarction, in patients with CP infection (1). However, other
cytokine gene polymorphisms, such as IL-6 and IL-10, were also
reported to be associated with CAD as well as inflammatory
diseases. In addition to the IL-1 gene polymorphisms, they may be
contributing to the development of CAD associated with CP
infection. We will continue to seek genetic factors influencing the
susceptibility to CAD associated with CP or other infections.
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Patients With CHF and Depression
Have Greater Risk of Mortality and
Morbidity Than Patients Without Depression
With great respect and interest, we read the recently published
study by Vaccarino et al. (1) in the Journal. That study supports our
previous findings, presented at the annual meetings of the Amer-
ican Psychiatric Association (2) and the American Heart Associ-
ation (3) and was just published a day before in the Archives of
Internal Medicine this month, that the short-term prognosis of
patients with heart failure (HF) and comorbid depression is much
worse than that of such patients without depression.
Vaccarino and colleagues assessed the level of depressive symp-
toms by means of the Geriatric Depression Scale (GDS) on 391
patients aged 50 or older who were hospitalized with HF. They
followed the patients for six months and assessed mortality and
functional capacity in activities of daily living (ADL). They found
that mortality at six months was two to three times higher in
patients with greater depressive symptoms than in those with lesser
depressive symptoms or those considered to have normal mood.
Patients with moderate to severe depressive symptoms also showed
significant functional declines during follow-up. Apparently, the
covariates of age, gender, race and education were not associated
with the relationships of depression to mortality and functional
decline; but when the statistical model was adjusted for other
variables, such as prior infarction, diabetes, prior admission for
HF, certain limiting factors of ADL and several baseline clinical
features (systolic blood pressure, serum creatinine, pulse and left
ventricular ejection fraction), in addition to these demographic
characteristics, the adverse relation between depression and mor-
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